FDA grants priority review to Gilead Sciences’ hepatitis C combination drug
Gilead filed a new drug application for the treatment, a combination of the company’s Sovaldi with velpatasvir, in October last year. A final decision from the FDA is
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
The companies have signed a collaboration agreement under which Pfizer and Merck will combine their avelumab cancer drug with Syndax’s entinostat, a treatment currently being studied in patients
This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in scientific discovery and research with Vault Bioventures’ proven capability in clinical and regulatory development
Preeclampsia is one of the most common medical complications of pregnancy, and a leading cause of premature births, stillbirths and early neonatal and maternal deaths. Severe preeclampsia occurs